A Leader in Scientific Breakthroughs
BrightFocus Foundation is a premier private funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. We are currently managing a nearly $75+ million global portfolio of more than 280 scientific projects.
Learn more about grants awarded in the most current fiscal year (nearly $25 million in funding for 95new awards in FY2022).
A team including two BrightFocus-funded Alzheimer’s disease researchers discovered that deteriorating neurons are a source of human brain inflammation, which could pave the way for therapeutics to prevent or treat Alzheimer’s disease.
A new blood test that could facilitate a more accurate diagnosis of Alzheimer’s during the initial phases of the disease is on the way—rooted in critical early support from Alzheimer’s Disease Research, a program of BrightFocus Foundation. Catching the disease as soon as possible offers affected individuals the greatest gift of all—more time to spend with loved ones and explore disease management and treatment options.
Clinical trial results released Nov. 29 for lecanemab, a drug targeting early Alzheimer’s disease, reported a moderate slowing of cognitive decline in patients by 25% through the removal of amyloid-beta (Aβ) in the brain.